As reported earlier, an intraperitoneal injection of 1 gg of endotoxin (ET) from Serratia marcescens rendered mice resistant against the nonspecific mouse ascites tumor TA3-Ha upon challenge 24 h after pretreatment with ET. Further studies were aimed at the elaboration of conditions which achieved maximal resistance. It appears that (i) a 10-,gg dose of ET was approximately the optimal dose for protection; (ii) pretreatment with ET 3 to 0 days prior to tumor challenge gave best protection; and (iii) the intravenous injection of ET showed a lower protection against the tumor than intraperitoneal application. Studies on the mechanism of ET protection indicate that (i) ET does not have a direct cytotoxic effect on tumor cells; (ii) normal spleen cells exposed to ET in vitro can adoptively transfer protection against tumor; and (iii) spleen cells activated in vivo by intravenous injection of ET can adoptively transfer protection. The possible involvement of mononuclear cells is discussed.
In studies on a well-defined nonspecific mouse ascites carcinoma (TA3-Ha), we observed that the threshold dose of tumor was greatly increased in mice with active or latent infantile diarrhea and in older mice. Conversely, a very low threshold tumor dose was sufficient in specific pathogen-free mice and healthy young mice. To study this phenomenon and to investigate which component of bacterial cells induces this nonspecific tumor resistance, mice were challenged intraperitoneally (i.p.) with 1 gg of purified Serratia marcescens endotoxin and challenged i.p. with 4 TD,0 of TA3-Ha after 24 h. (TD50 = number of viable tumor cells causing 50% mortality.) Significant resistance against tumor was observed (5). In this study, optimal conditions for such protection were investigated, including the effects of (i) various doses of endotoxin (ET); (ii) various time intervals between ET administration and tumor challenge; and (iii) various routes of injection of ET. The mechanism of the anti-tumor effects of ET was also studied.
MATERIALS AND METHODS
Mice. C57bl/10 (H2b) female mice were purchased from the Jackson Laboratories, Bar Harbor, Me. ICR female mice were bred in our laboratory. The age of mice for most of the experiments was from 6 to 8 weeks.
Preparation of tumor cells. The origin of TA3-Ha tumor and preparation of tumor cell suspensions has been described in a previous report (5) . In all experiments the tumor cells were obtained directly from A/J maintenance mice. The TD50 of these tumor cells in ICR mice was highly reproducible at 1,000 viable cells injected i.p. The TD,0 in C57bl/10 mice was more variable, the average being approximately 104 viable cells injected i.p. In all cases, tumor challenge was injected i.p.
ET. The modified Boivin procedure for the extraction of ET has been described (9) . Lyophilized ET was suspended in saline and solubilized by treatment with 0.1 N NaOH for 5 min at 18 C. The pH was adjusted to 7.0.
In vitro exposure of tumor cells to ET. Tumor cells were collected from A/J maintenance mice as described earlier (5), washed and resuspended at a concentration of 106 cells per ml in medium 199 supplemented with 10% fetal calf serum. ET, at 100 ,gg/106 cells, was added to the culture. One, 3, 7, and 9 h after incubation at 37 C, viability of tumor cells was determined with trypan blue. After 1.5 and 7 h of incubation, the cells were washed three times with Hanks balanced salt solution, and 103 (TD50) tumor cells were injected into ICR mice.
Preparation of spleen cell suspensions. Spleen cells were prepared in a similar way to that described in the previous report (5) of incubation, the viability of tumor cells was not reduced in the control cultures or in cultures containing ET.
Tumorigenicity of TA3-Ha cells incubated with ET. As the tumorigenicity of TA3-Ha cells may not be revealed by the dye exclusion assay, tumor cells which had been exposed to ET were taken from the culture after 1.5 and 7 h of incubation, and 1 TD50 was injected, after three washes, into ICR mice. The results (Table 7) showed that tumor cells obtained from cultures either with or without ET resulted in approximately 50% mortality in ICR mice. The possibility of direct toxicity of ET to tumor cells thus could be excluded.
Lymphoblast transformation by the stimulation of ET. The effect of ET on the spleen cells was measured in vitro by lymphoblast transformation, which is measured by deoxyribonucleic acid (DNA) synthesis in the Tindependent lymphocyte population (3). Vari (Fig. 1) , which was an 11-fold increase in stimulation as com- Table 2 ).
The reproducibility and accuracy of the limulus lysate assay, using lysate prepared by J. Levin, is exceptionally high. We presently use this assay routinely for quantitation of bacterial endotoxins.
Adoptive transfer of spleen cells of mice injected i.v. with 10 ug of ET. As noted, i.v. injection of small doses of ET did not protect mice against the TA3-Ha tumor (Table 5 ). Since it has been shown that, a few hours after i.v. injection, almost all ET could be found in mouse lungs, liver, and spleen (4), the lack of protection was assumed to be due to inability of ET and/or activated cells to reach the tumor site, which was located i.p. To prove that cells could be activated in vivo, 10 ug of ET was injected i.v. into ICR mice. After 24 h, spleens were removed and 107 spleen cells were adoptively transferred i.p. into normal ICR recipients, followed by a 3 TD50 tumor challenge (Table 9 ). Significant protection was obtained by the adoptive transfer of 107 spleen cells, whereas treatment with 107 normal spleen cells did not give protection. The ET content in the 107 spleen cell sonic extract was less than 0.02 MAg, as determined by the limulus lysate clotting assay.
DISCUSSION
Regarding the mechanism of the observed anti-tumor effect of ET, we have considered several possibilities. First, ET may have a (1), that the growth of lymphoma cells was not influenced by the presence of ET in the cell culture. Further, the tumor we used was always in ascites form, in which the vascularization of tumor does not occur. Therefore, vascular damage in the tumor by the hemodynamic effect of ET plays little if any role in the inhibition of tumor growth.
Since protection could be transferred adoptively by ET-activated mononuclear cells, it is assumed that either macrophages or lymphocytes play a significant role in this anti-tumor phenomenon. It has been suggested by others that ET-activated macrophages play a major role in the inhibition of tumor growth in a nonspecific fashion (1, 6, 10) . This is a likely mechanism for the observation reported here.
The anti-tumor effect of low doses of ET was greatest if it was applied 3 to 0 days prior to tumor challenge. The anti-tumor effect was directly demonstrable when ET was administered "locally," implying the involvement of activated peritoneal cells which consist of 70 to 80% macrophages. Tripodi et al. (16) , in a mouse sarcoma system, and Parr et al. (10) , in a lymphoma system, reported similar enhancement of tumor resistance localized to the site of ET application.
It is also possible that the adjuvant effect of ET on tumor-specific antibody synthesis may lead to "arming" of macrophages (17). It has been reported that ET can enhance the uptake of cytophilic antibodies by macrophages (15) . An implication of the involvement of specific immune responses could be the observation by Parr et al. (10) that the effect of ET on inhibition of tumor growth was correlated with the immunogenicity of the tumors studied.
Many reports have indicated that the blastogenic effect of ET is on the B-cell population (3, 11, 14) . It has been confirmed by us that ET could stimulate DNA synthesis in mouse spleen cell preparations. The peak of this stimulation is in the range of 10 gg. The possible role of B cells in cytotoxicity has been suggested (12, 13) , and it was found that this B-cell-mediated cytotoxicity could be induced by a small amount of immunoglobulin G antibodies. Therefore, it is possible that in our system, when mice were treated with ET, B-cells were activated and, at the same time, a small amount of specific anti-tumor antibodies was synthesized earlier than normally expected due to the adjuvant effect of ET. These small amounts of specific antibodies could enhance the cytotoxicity of the B-cells.
However, it has been demonstrated by Moller et al. (2) that ET-activated B-cells did not have detectable cytotoxicity in their system. In preliminary experiments we have found that glycolipid from Salmonella minnesota R595, which is a better stimulant of in vitro transformation than lipopolysaccharide (LPS), had less protective effect toward TA3-Ha than LPS. Furthermore, spleen cells at the peak of stimulation, which is 3 days, did not exert the same antitumor effect as 5-h-incubated spleen cells. These observations seem to indicate that the blastogenic effect (measured as described here) and the anti-tumor effect of ET are not correlated phenomena.
The actual involvement of the cells is most likely much more complicated, since cooperation among T-cells, B-cells, and macrophages exists. A better approach to this problem is the study of the anti-tumor effect by separated adhering cells and nonadhering T-and B-cells. These experiments are in progress in our laboratories.
In conclusion, the data reported here 
